The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
NCT01270191 on ClinicalTrials.gov · last registry update 2013-06-27
An unusually large phase 4: 160 participants, more than double the 75 typical for the stage. Its estimated completion date, December 2014, has passed with no update to the record. Primary outcome, as filed: the time of glycemic remission and remission rate. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Taipei Veterans General Hospital, Taiwan
- Sponsor type
- Other Gov
- Enrollment
- 160
- Started
- 2010-11
- Primary completion
- 2014-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
the time of glycemic remission and remission rate
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.